Association of elevated fractional exhaled nitric oxide concentration and blood eosinophil count with severe asthma exacerbations

Research output: Contribution to journalArticle

Standard

Association of elevated fractional exhaled nitric oxide concentration and blood eosinophil count with severe asthma exacerbations. / Price, David B.; Bosnic-Anticevich, Sinthia; Pavord, Ian D.; Roche, Nicolas; Halpin, David M.G.; Bjermer, Leif; Usmani, Omar S.; Brusselle, Guy; Ming, Simon Wan Yau; Rastogi, Sarang.

In: Clinical and Translational Allergy, Vol. 9, No. 1, 41, 21.08.2019.

Research output: Contribution to journalArticle

Harvard

Price, DB, Bosnic-Anticevich, S, Pavord, ID, Roche, N, Halpin, DMG, Bjermer, L, Usmani, OS, Brusselle, G, Ming, SWY & Rastogi, S 2019, 'Association of elevated fractional exhaled nitric oxide concentration and blood eosinophil count with severe asthma exacerbations', Clinical and Translational Allergy, vol. 9, no. 1, 41. https://doi.org/10.1186/s13601-019-0282-7

APA

CBE

MLA

Vancouver

Author

Price, David B. ; Bosnic-Anticevich, Sinthia ; Pavord, Ian D. ; Roche, Nicolas ; Halpin, David M.G. ; Bjermer, Leif ; Usmani, Omar S. ; Brusselle, Guy ; Ming, Simon Wan Yau ; Rastogi, Sarang. / Association of elevated fractional exhaled nitric oxide concentration and blood eosinophil count with severe asthma exacerbations. In: Clinical and Translational Allergy. 2019 ; Vol. 9, No. 1.

RIS

TY - JOUR

T1 - Association of elevated fractional exhaled nitric oxide concentration and blood eosinophil count with severe asthma exacerbations

AU - Price, David B.

AU - Bosnic-Anticevich, Sinthia

AU - Pavord, Ian D.

AU - Roche, Nicolas

AU - Halpin, David M.G.

AU - Bjermer, Leif

AU - Usmani, Omar S.

AU - Brusselle, Guy

AU - Ming, Simon Wan Yau

AU - Rastogi, Sarang

PY - 2019/8/21

Y1 - 2019/8/21

N2 - Background: Blood eosinophil count (BEC) and fractional exhaled nitric oxide (FeNO) concentration are established biomarkers in asthma, associated particularly with the risk of exacerbations. We evaluated the relationship of BEC and FeNO as complementary and independent biomarkers of severe asthma exacerbations. Methods: This observational study included data from the Optimum Patient Care Research Database. Asthma patients (18-80 years) with valid continuous data for 1 year before FeNO reading, ≥ 1 inhaled corticosteroid prescription, and BEC recorded ≤ 5 years before FeNO reading were separated into cohorts. Categorisation 1 was based on the American Thoracic Society criteria for elevated FeNO concentration (high: ≥ 50 ppb; non-high: < 25 ppb) and BEC (high: ≥ 0.300 × 109 cells/L; non-high: < 0.300 × 109 cells/L). Categorisation 2 (FeNO concentration, high: ≥ 35 ppb; non-high: < 35 ppb) was based on prior research. Reference groups included patients with neither biomarker raised. Results: In categorisation 1, patients with either high FeNO or high BEC (n = 200) had a numerically greater exacerbation rate (unadjusted rate ratio, 1.31 [95% confidence interval: 0.97, 1.76]) compared with patients in the reference group. Combination of high FeNO and high BEC (n = 27) resulted in a significantly greater exacerbation rate (3.67 [1.49, 9.04]). Similarly, for categorisation 2, when both biomarkers were raised (n = 53), a significantly greater exacerbation rate was observed (1.72 [1.00, 2.93]). Conclusion: The combination of high FeNO and high BEC was associated with significantly increased severe exacerbation rates in the year preceding FeNO reading, suggesting that combining FeNO and BEC measurements in primary care may identify asthma patients at risk of exacerbations.

AB - Background: Blood eosinophil count (BEC) and fractional exhaled nitric oxide (FeNO) concentration are established biomarkers in asthma, associated particularly with the risk of exacerbations. We evaluated the relationship of BEC and FeNO as complementary and independent biomarkers of severe asthma exacerbations. Methods: This observational study included data from the Optimum Patient Care Research Database. Asthma patients (18-80 years) with valid continuous data for 1 year before FeNO reading, ≥ 1 inhaled corticosteroid prescription, and BEC recorded ≤ 5 years before FeNO reading were separated into cohorts. Categorisation 1 was based on the American Thoracic Society criteria for elevated FeNO concentration (high: ≥ 50 ppb; non-high: < 25 ppb) and BEC (high: ≥ 0.300 × 109 cells/L; non-high: < 0.300 × 109 cells/L). Categorisation 2 (FeNO concentration, high: ≥ 35 ppb; non-high: < 35 ppb) was based on prior research. Reference groups included patients with neither biomarker raised. Results: In categorisation 1, patients with either high FeNO or high BEC (n = 200) had a numerically greater exacerbation rate (unadjusted rate ratio, 1.31 [95% confidence interval: 0.97, 1.76]) compared with patients in the reference group. Combination of high FeNO and high BEC (n = 27) resulted in a significantly greater exacerbation rate (3.67 [1.49, 9.04]). Similarly, for categorisation 2, when both biomarkers were raised (n = 53), a significantly greater exacerbation rate was observed (1.72 [1.00, 2.93]). Conclusion: The combination of high FeNO and high BEC was associated with significantly increased severe exacerbation rates in the year preceding FeNO reading, suggesting that combining FeNO and BEC measurements in primary care may identify asthma patients at risk of exacerbations.

KW - Asthma

KW - Blood eosinophils

KW - Exhaled airway markers

KW - Nitric oxide

U2 - 10.1186/s13601-019-0282-7

DO - 10.1186/s13601-019-0282-7

M3 - Article

VL - 9

JO - Clinical and Translational Allergy

T2 - Clinical and Translational Allergy

JF - Clinical and Translational Allergy

SN - 2045-7022

IS - 1

M1 - 41

ER -